SCHEMBL3403753

SCHEMBL3403753

Cc1ccc(I)cn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23474083 0.83 HPGDS (0.41)
SCHEMBL23176993 0.80 HPGDS (0.46)
SCHEMBL10765894 0.71 HDAC6 (0.60)
SCHEMBL31218494 0.71
SCHEMBL198094 0.71
SCHEMBL676678 0.71 HPGDS (0.56)
SCHEMBL31243289 0.71
SCHEMBL31030 0.71
SCHEMBL4390590 0.71 CCR1 (0.46)
SCHEMBL15780420 0.69 HDAC8 (0.44)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 546 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260091048-A1 GIP RECEPTOR AGONIST COMPOUNDS LILLY CO ELI (US) 2026-04-02 US disclosed
US-20250388582-A1 NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF ILDONG PHARMACEUTICAL CO LTD (KR) 2025-12-25 US disclosed
US-20250320196-A1 APOL1 INHIBITORS AND METHODS OF USES THEREOF MAZE THERAPEUTICS INC (US) 2025-10-16 US disclosed
US-12338240-B2 Nonmuscle myosin ii inhibitors THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2025-06-24 US disclosed
US-20250163056-A1 NONMUSCLE MYOSIN II INHIBITORS THE UNIV OF FLORIDA RESEARCH FOUNDATION INC (US) 2025-05-22 US disclosed
EP-4556476-A1 NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF Ildong Pharmaceutical Co., Ltd. (KR) 2025-05-21 EP disclosed
CN-119855817-A Heterocyclic alkynyl-substituted amide derivatives, preparation method and application thereof 成都微芯药业有限公司 2025-04-18 CN disclosed
WO-2025026381-A1 HETEROCYCLYLALKYNYL SUBSTITUTED AMIDE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF 成都微芯药业有限公司 2025-02-06 WO disclosed
US-20240398805-A1 QUINAZOLINE DERIVED COMPOUNDS AS EGFR INHIBITORS AND THEIR USES THEREOF ACCUTAR BIOTECHNOLOGY INC. (US) 2024-12-05 US disclosed
US-20240376044-A1 METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2024-11-14 US disclosed
US-20080300266-A1 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists ELI LILLY AND COMPANY (US) 2008-12-04 US disclosed
US-20080300266-A1 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists ELI LILLY AND COMPANY (US) 2008-12-04 US disclosed
WO-2007089034-A1 BENZOXAZINES AND RELATED NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS USEFUL AS MINERALOCORTICOID RECEPTOR MODULATING AGENTS MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-08-09 WO disclosed
US-20070020479-A1 Luminescent-polymer composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-01-25 US disclosed
US-20070020479-A1 Luminescent-polymer composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-01-25 US disclosed
WO-2006044454-A1 1-(HETERO)ARYL-3-AMINO-PYROLLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2006-04-27 WO disclosed
EP-0970083-B1 7a-HETEROCYCLE-SUBSTITUTED HEXAHYDRO-1H-PYRROLIZINE COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION ABBOTT LAB (US) 2003-04-16 EP disclosed
EP-0970083-A1 7a-HETEROCYCLE-SUBSTITUTED HEXAHYDRO-1H-PYRROLIZINE COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION Abbott Laboratories (US) 2000-01-12 EP disclosed
WO-1998037082-A1 7a-HETEROCYCLE-SUBSTITUTED HEXAHYDRO-1H-PYRROLIZINE COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION ABBOTT LABORATORIES (US) 1998-08-27 WO disclosed
US-5733912-A NERVOUS SYSTEM DISORDERS IN NERVE CELLS ABBOTT LABORATORIES (US) 1998-03-31 US disclosed